Seminars in Oncology
Volume 33 , Pages 8-14 , June 2006

Exposure to Anthracyclines During Childhood Causes Cardiac Injury

  • Steven E. Lipshultz

      Affiliations

    • Dr Lipshultz has received grant support from Pfizer, Roche Diagnostics, and Chiron Biopharmaceuticals.
    • Corresponding Author InformationAddress reprint requests to Steven E. Lipshultz, MD, University of Miami Miller School of Medicine, Department of Pediatrics, 9th Floor, Mailman Center for Child Development, Sylvester Comprehensive Cancer Center, 1601 NW 12th Ave, Miami, FL 33136.

References 

  1. Silverman LB , Gelber RD , Dalton VK , et al.  Improved outcome for children with acute lymphoblastic leukemia (results of Dana-Farber Consortium Protocol 91-01) . Blood . 2001;97:1211–1218
  2. Lipshultz SE , Rifai N , Dalton VM , et al.  The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia . N Engl J Med . 2004;351:145–153
  3. Minotti G , Menna P , Salvatorelli E , et al.  Anthracyclines (Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity) . Pharmacol Rev . 2004;56:185–229
  4. Adams MJ , Hardenbergh PH , Constine LS , et al.  Radiation-associated cardiovascular disease . Crit Rev Oncol Hematol . 2003;45:55–75
  5. Adams MJ , Lipshultz SE , Schwartz C , et al.  Radiation-associated cardiovascular disease (Manifestations and management) . Semin Radiat Oncol . 2003;13:346–356
  6. Adams MJ , Lipsitz SR , Colan SD , et al.  Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy . J Clin Oncol . 2004;22:3139–3148
  7. Adams MJ , Lipshultz SE . Pathophysiology of anthracycline- and radiation-associated cardiomyopathies (implications for screening and prevention) . Pediatr Blood Cancer . 2005;44:600–606
  8. Adams MJ , Constine LS , Lipshultz SE . Radiation . In:  Crawford MH ,  DiMarco JP ,  Paulus WJ editor. Cardiology. . Ed 2. Edinburgh: Mosby; 2004;p. 1583–1590
  9. Lipshultz SE , Colan SD , Gelber RD , et al.  Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood . N Engl J Med . 1991;324:808–815
  10. Lipshultz SE , Lipsitz SR , Mone SM , et al.  Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer . N Engl J Med . 1995;332:1738–1743
  11. Lipshultz SE , Lipsitz SR , Sallan SE , et al.  Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia . J Clin Oncol . 2005;23:2629–2636
  12. Lipshultz SE , Miller TL . Establishing norms for echocardiographic measurements of cardiovascular structures and function in children . J Appl Physiol . 2005;99:386–388
  13. Constine LS , Lipshultz SE . Heart of the matter:Risk factors for premature cardiovascular disease in cancer survivors. In:  Perry MC editors. American Society of Clinical Oncology Educational Book 40th Annual Meeting.. 2004;p. 418–424
  14. Hinkle AS , Proukou CB , Deshpande SS , et al.  Cardiovascular complications (Chemotherapy to include prevention strategies). In:  Wallace H ,  Green D editor. Late Effects of Childhood Cancer.. London: Edward Arnold; 2004;p. 85–100
  15. Lipshultz SE , Colan SD . Cardiovascular trials in long-term survivors of childhood cancer . J Clin Oncol . 2004;22:769–773
  16. Adams MJ , Duffy SA , Constine LS , et al.  Cardiovascular effects of cancer therapy . In:  Schwartz CL ,  Hobbie WL ,  Constine LS ,  Ruccione KS editor. Survivors of Childhood and Adolescent Cancer . Berlin-Heidelberg: Springer-Verlag; 2005;p. 133–159
  17. Hale ER , Lipshultz SE , Constine LS . Latent cardiac injury following the double-edged sword of chemotherapy and radiation . In:  Perry MC editors. American Society of Clinical Oncology 2005 Educational Book . Alexandria, VA: American Society of Clinical Oncology; 2005;p. 739–746
  18. Wouters KA , Kremer LCM , Miller TL , et al.  Protecting against anthracycline-induced myocardial damage (A review of the most promising strategies) . Br J Haematol . 2005;131:561–578
  19. Simbre VC , Duffy SA , Dadlani GH , et al.  Cardiotoxicity of cancer chemotherapy (Implications for children) . Paediatr Drugs . 2005;7:187–202
  20. Kremer LC , van der Pal HJ , Offringa M , et al.  Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children (A systematic review) . Ann Oncol . 2002;13:819–829
  21. Sorensen K , Levitt GA , Bull C , et al.  Late anthracycline cardiotoxicity after childhood cancer (A prospective longitudinal study) . Cancer . 2003;97:1991–1998
  22. Kremer LC , van Dalen EC , Offringa M , et al.  Anthracycline-induced clinical heart failure in a cohort of 607 children (Long-term follow-up study) . J Clin Oncol . 2001;19:191–196
  23. Panteghini M . Role and importance of biochemical markers in clinical cardiology . Eur Heart J . 2004;25:1187–1196
  24. Herman EH , Zhang J , Rifai N , et al.  The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity . Cancer Chemother Pharmacol . 2001;48:297–304
  25. Lipshultz SE , Rifai N , Sallan SE , et al.  Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury . Circulation . 1997;96:2641–2648
  26. Hinkle AS , Proukou C , French CA , et al.  A clinic-based, comprehensive care model for studying late effects in long-term survivors of pediatric illnesses . Pediatrics . 2004;113:1141–1145
  27. The SOLVD Investigators . Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions . N Engl J Med . 1992;327:685–691
  28. Cohn JN . Prevention of heart failure . Cardiology . 1999;92:22–25
  29. Yusuf S , Sleight P , Pogue J , et al.  The Heart Outcomes Prevention Evaluation Study Investigators   Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients . N Engl J Med . 2000;342:145–153
  30. Silber JH , Cnaan A , Clark BJ , et al.  Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines . J Clin Oncol . 2004;22:820–828
  31. Lipshultz SE , Lipsitz SR , Sallan SE , et al.  Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer . J Clin Oncol . 2002;20:4517–4522
  32. Lipshultz SE , Giantris AL , Lipsitz SR , et al.  Doxorubicin administration by continuous infusion is not cardioprotective (The Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol) . J Clin Oncol . 2002;20:1677–1682
  33. Levitt GA , Dorup I , Sorensen K , et al.  Does anthracycline administration by infusion in children affect late cardiotoxicity? . Br J Haematol . 2004;124:463–468
  34. Feldman JE , Jones SE , Weisberg SR , et al.  Advanced small cell lung cancer treated with CAV (cyclophosphamide + adriamycin® + vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR-529, ICF-187, Zinecard® . Proc Am Soc Clin Oncol . 1992;11:A993; (abstr)
  35. Lopez M , Vici P , Di LK , et al.  Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas . J Clin Oncol . 1998;16:86–92
  36. Marty M , Paraport B , Llombart A , et al.  A phase III study to investigate the cardioprotective potential of dexrazoxane in advanced/metastatic breast cancer patients undergoing anthracycline-based chemotherapy [poster presentation] . Breast Cancer Res Treat . 2004;88:S201–S202 (abstr)
  37. Speyer JL , Green MD , Zeleniuch-Jacquotte A , et al.  ICRF-187 permits longer treatment with doxorubicin in women with breast cancer . J Clin Oncol . 1992;10:117–127
  38. Swain SM , Whaley FS , Gerber MC , et al.  Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer . J Clin Oncol . 1997;15:1318–1332
  39. ten bokkel Huinink WW , Schreuder JE , Dubbelman R , et al.  ICRF-187 protects against doxorubicin-induced cardiomyopathy . Ann Oncol . 1992;3:S221; (abstr)
  40. Venturini M , Michelotti A , Del ML , et al.  Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer . J Clin Oncol . 1996;14:3112–3120
  41. Wexler LH , Andrich MP , Venzon D , et al.  Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin . J Clin Oncol . 1996;14:362–372
  42. Link K , Moell C , Garwicz S , et al.  Growth hormone deficiency predicts cardiovascular risk in young adults treated for acute lymphoblastic leukemia in childhood . J Clin Endocrinol Metab . 2004;89:5003–5012
  43. Lipshultz SE , Vlach SA , Lipsitz SR , et al.  Cardiac changes associated with growth hormone therapy among children treated with anthracyclines . Pediatrics . 2005;115:1613–1622
  44. Ryoke T , Gu Y , Mao L , et al.  Progressive cardiac dysfunction and fibrosis in the cardiomyopathic hamster and effects of growth hormone and angiotensin-converting enzyme inhibition . Circulation . 1999;100:1734–1743
  45. Salerno M , Esposito V , Spinelli L , et al.  Left ventricular mass and function in children with GH deficiency before and during 12 months GH replacement therapy . Clin Endocrinol (Oxf) . 2004;60:630–636
  46. US National Cancer Institute Workshop on Paediatric Oncology Late Effects of Childhood Cancer Networks. 2002
  47. Lipshultz SE , Lipsitz SR , Hinkle AS , et al.  Cardiovascular status, subsequent risk, and associated factors in long-term survivors of childhood cancer in a population-based NCI study . Circulation . 2005;112:II476; (abstr 2292)
  48. Miller TL , Lipsitz S , French C , et al.  Predictors of bone mineral density in pediatric cancer survivors . J Clin Oncol . 2005;23:804s; (abstr 8518)
  49. Miller TL , Horgan S , Lipshultz SE . Exercise rehabilitation of pediatric patients with cardiovascular disease . Prog Pediatr Cardiol . 2005;20:27–37
  50. Sallan SE , Lipshultz SE . Wise up (Do not do it without protection!) . Pediatr Blood Cancer . 2005;45:872–873

PII: S0093-7754(06)00207-7

doi: 10.1053/j.seminoncol.2006.04.019

Seminars in Oncology
Volume 33 , Pages 8-14 , June 2006

Article Tools

* Image Usage & Resolution